The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps

  • Bernadette ThomasEmail author
Microvascular Complications—Nephropathy (M Afkarian and B Roshanravan, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Microvascular Complications—Nephropathy


Purpose of Review

Diabetes mellitus prevalence is increasing throughout the world as a consequence of growing rates of obesity, metabolic syndrome, and westernization of lifestyle. It is currently unknown to what extent these trends affect the global burden of diabetic kidney disease (DKD). This review seeks to describe the global burden of DKD and how it has changed throughout time using recently released results of the Global Burden of Disease 2017 Study.

Recent Findings

DKD prevalence has remained fairly stable at the global level and among many world regions since 1990. At the global level, the proportion of DKD deaths relative to other types of CKD is increasing.


Certain world regions still have very high rates of DKD, whereas other world regions have decreasing prevalence and mortality. Screening will likely play an important role in mitigating the growing burden within high-risk regions.


Diabetic nephropathy Global burden of diabetic kidney disease Gender and diabetic kidney disease 


Compliance with Ethical Standards

Conflict of Interest

The author declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Supplementary material

11892_2019_1133_MOESM1_ESM.pdf (123 kb)
Appendix Figure 1 Proportion of chronic kidney disease deaths due to diabetic kidney disease at global, regional, and country levels for the years 1990 and 2017. (PDF 123 kb)


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. DKD: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–76.CrossRefGoogle Scholar
  2. 2.
    Brown WV. Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection. Am J Cardiol. 2008;102(12A):10L–3L. Scholar
  3. 3.
    Giorda CB, Carna P, Salomone M, Picariello R, Costa G, Tartaglino B, et al. Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes. Acta Diabetol. 2018;55(7):733–40. Scholar
  4. 4.
    •• Collaborators GBDRF. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–94. Most recent update to the Global Burden of Disease Study which describes the effects of 84 risk factors on loss of health and life throughout the world for time periods between 1990 and 2017. CrossRefGoogle Scholar
  5. 5.
    •• Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–88. Most recent update to the Global Burden of Disease Study which ranks causes of death throughout the world for time periods between 1990 and 2017. This study includes chronic kidney disease and CKD subtypes. CrossRefGoogle Scholar
  6. 6.
    Popkin BM. Nutrition transition and the global diabetes epidemic. Current diabetes reports. 2015;15(9):64. Scholar
  7. 7.
    Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status? TheScientificWorldJOURNAL. 2014;2014:964236–7. Scholar
  8. 8.
    Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3–21. Scholar
  9. 9.
    Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8. Scholar
  10. 10.
    Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of Disease study 2017. Lancet. 2018;392(10159):1789–858. Scholar
  11. 11.
    Dagenais GR, Gerstein HC, Zhang X, McQueen M, Lear S, Lopez-Jaramillo P, et al. Variations in diabetes Prevalence in low-, middle-, and high-income countries: results from the prospective urban and rural epidemiological study. Diabetes Care. 2016;39(5):780–7. Scholar
  12. 12.
    Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–30. Scholar
  13. 13.
    Satirapoj B, Adler SG. Prevalence and management of DKD in Western countries. Kidney diseases. 2015;1(1):61–70. Scholar
  14. 14.
    Kume S, Araki SI, Ugi S, Morino K, Koya D, Nishio Y, et al. Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes, 1996-2014. Journal of diabetes investigation. 2018.
  15. 15.
    Tan KHX, Barr ELM, Koshkina V, Ma S, Kowlessur S, Magliano DJ, et al. Diabetes mellitus prevalence is increasing in south Asians but is stable in Chinese living in Singapore and Mauritius. Journal of diabetes. 2017;9(9):855–64. Scholar
  16. 16.
    Tan J. End stage renal disease in Brunei Darussalam - report from the first Brunei Dialysis transplant registry (BDTR). Ren Fail. 2013;35(8):1101–4. Scholar
  17. 17.
  18. 18.
    Stel VS, Awadhpersad R, Pippias M, Ferrer-Alamar M, Finne P, Fraser SD, et al. International comparison of trends in patients commencing renal replacement therapy by primary renal disease. Nephrology. 2018.
  19. 19.
    van den Donk M, Sandbaek A, Borch-Johnsen K, Lauritzen T, Simmons RK, Wareham NJ, et al. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. Diabetic medicine: a journal of the British Diabetic Association. 2011;28(11):1416–24. Scholar
  20. 20.
    Sargeant LA, Simmons RK, Barling RS, Butler R, Williams KM, Prevost AT, et al. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabetic medicine: a journal of the British Diabetic Association. 2010;27(9):995–1003. Scholar
  21. 21.
    Simmons RK, Griffin SJ, Lauritzen T, Sandbaek A. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia. 2017;60(11):2192–9. Scholar
  22. 22.
    Feldman AL, Griffin SJ, Fharm E, Norberg M, Wennberg P, Weinehall L, et al. Screening for type 2 diabetes: do screen-detected cases fare better? Diabetologia. 2017;60(11):2200–9. Scholar
  23. 23.
    Lin S, Hufanga S, Linhart C, Morrell S, Taylor R, Magliano DJ, et al. Diabetes and obesity trends in Tonga over 40 years. Asia Pac J Public Health. 2016;28(6):475–85. Scholar
  24. 24.
    Lin S, Naseri T, Linhart C, Morrell S, Taylor R, McGarvey ST, et al. Trends in diabetes and obesity in Samoa over 35 years, 1978-2013. Diabetic medicine: a journal of the British Diabetic Association. 2017;34(5):654–61. Scholar
  25. 25.
    Lin S, Tukana I, Linhart C, Morrell S, Taylor R, Vatucawaqa P, et al. Diabetes and obesity trends in Fiji over 30 years. Journal of diabetes. 2016;8(4):533–43. Scholar
  26. 26.
    Morrell S, Lin S, Tukana I, Linhart C, Taylor R, Vatucawaqa P, et al. Diabetes incidence and projections from prevalence surveys in Fiji. Popul Health Metrics. 2016;14:45. Scholar
  27. 27.
    Krishnan A, Chandra Y, Malani J, Jesudason S, Sen S, Ritchie AG. End-stage kidney disease in Fiji. Intern Med J. 2018.
  28. 28.
    Hamid S, Dunsiger S, Seiden A, Nu'usolia O, Tuitele J, DePue JD, et al. Impact of a diabetes control and management intervention on health care utilization in American Samoa. Chronic illness. 2014;10(2):122–34. Scholar
  29. 29.
    Cobo G, Hecking M, Port FK, Exner I, Lindholm B, Stenvinkel P, et al. Sex and gender differences in chronic kidney disease: progression to end-stage renal disease and haemodialysis. Clin Sci. 2016;130(14):1147–63. Scholar
  30. 30.
    • Carrero JJ, Hecking M, Chesnaye NC, Jager KJ. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nature reviews Nephrology. 2018;14(3):151–64. One of the few studies to take an in-depth look at possible ways in which gender plays a role in kidney disease incidence and progression. CrossRefPubMedGoogle Scholar
  31. 31.
    Carrero JJ, Hecking M, Ulasi I, Sola L, Thomas B. Chronic kidney disease, gender, and access to care: a global perspective. Semin Nephrol. 2017;37(3):296–308. Scholar
  32. 32.
    Saran R, Li Y, Robinson B, Abbott KC, Agodoa LY, Ayanian J, et al. US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2016;67(3 Suppl 1):Svii, S1–305. Scholar
  33. 33.
    United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018Google Scholar
  34. 34.
    Elling D, Surkan PJ, Enayati S, El-Khatib Z. Sex differences and risk factors for diabetes mellitus - an international study from 193 countries. Glob Health. 2018;14(1):118. Scholar
  35. 35.
    Collins AJ, Foley RN, Gilbertson DT, Chen SC. United States renal data system public health surveillance of chronic kidney disease and end-stage renal disease. Kidney international supplements. 2015;5(1):2–7. Scholar
  36. 36.
    Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2014;63(5):789–97. Scholar
  37. 37.
    Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14(21):1–184. Scholar
  38. 38.
    Moyer VA. Force USPST. Screening for chronic kidney disease: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157(8):567–70. Scholar
  39. 39.
    Thomas B, Wulf S, Bikbov B, Perico N, Cortinovis M, Courville de Vaccaro K, et al. Maintenance dialysis throughout the world in years 1990 and 2010. J Am Soc Nephrol. 2015;26(11):2621–33. Scholar
  40. 40.
    Chuengsaman P, Kasemsup V. PD first policy: Thailand’s response to the challenge of meeting the needs of patients with end-stage renal disease. Semin Nephrol. 2017;37(3):287–95. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Global HealthUniversity of WashingtonSeattleUSA

Personalised recommendations